Issue №129 · 2026-09-22

Daily Briefing · 2026-09-22

Physicians

Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapy

  • Beacon Therapeutics has found the light in a rare vision loss disease that has left larger companies in the dark. The biotech’s gene therapy for X-linked retinitis pigmentosa (XLRP) successfully improved visual acuity in
FierceBiotech ↗

← All issues

Smillin.

A daily 5-minute brief on AI, devices, and digital tools across physicians, dentistry, pharmacy, physician assistants, nursing, digital health, and Health OS. Read by clinicians.

Smillin

Connect

© 2026 Smillin Healthcare TechTermsPrivacyUSA · Daily 6 AM ET